A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin
Publication Type:
Journal Article
Authors:
Swain, M.G.;
Lai, M.Y.;
Shiffman, M.L.;
Cooksley, W.G.;
Stefan Zeuzem;
D. Dieterich;
Abergel, A.;
Pessoa, M.G.;
Lin, A.;
Tietz, A.;
Connell, E.V.;
Diago, M.Source:
Gastroenterology, Volume 139, Issue 5, p.1593-1601 (2010)
Keywords:
administration & dosage,
Alanine,
analysis,
Antiviral Agents,
Canada,
Comparative Study,
Dose-Response Relationship,Drug,
Drug Carriers,
drug effects,
drug therapy,
Drug Therapy,Combination,
Follow-Up Studies,
genetics,
HCV,
Health,
Hepacivirus,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hepatitis C,Chronic,
Human,
Humans,
Infection,
interferon,
Interferon Alfa-2a,
Interferon-alpha,
isolation & purification,
methods,
Multicenter Studies,
Patients,
peginterferon,
pegylated,
pegylated interferon,
Polyethylene Glycols,
Proteins,
Recombinant Proteins,
Research,
Research Support,
Retrospective Studies,
Ribavirin,
Rna,
Rna,Viral,
Serum,
sustained virologic response,
SVR,
therapeutic use,
therapy,
Time Factors,
treatment,
Treatment Outcome,
Viral Load,
virology
